Adial Pharmaceuticals has acquired Azora Therapeutics, gaining its lead drug candidate AT177, a colon-targeted treatment for ulcerative colitis designed to minimize systemic exposure and safety risks. Concurrently, Adial secured up to $64 million in private financing, including an initial $32 million upfront, to fund clinical development milestones, including Phase 1 trials planned for mid-2027. This acquisition and financing position Adial to advance a potentially best-in-class therapy addressing a significant unmet medical need in ulcerative colitis. The company also appointed Dr. Wendy Young to its board to support growth and drug development expertise.
On September 11, 2026, the Symbiosis cross-chain protocol was attacked, allowing an attacker to mint about 46 to 369 billion synthetic Bitcoin tokens (syBTC) without backing, causing a real loss of roughly $336,000. The vulnerability was due to poor ...
Standard Chartered forecasts the SKY token price to rise from $0.065 to $0.325 by the end of 2028, a fivefold increase driven by growth in the USDS stablecoin supply, agent borrowing, staking rewards, and token buybacks. The bank highlights SKY's uni...
Millrose Properties is rated a Strong Buy, trading at 9 times its 2027 FFO and offering a dividend yield above 10%. The company's growth prospects extend beyond its partnership with Lennar, especially through Other Agreements yielding 10.6%, which pr...
Solana (SOL) is under supply pressure due to Pump.fun's large ongoing sales totaling over 5 million SOL worth around $842 million, alongside whale investors shifting SOL into the STONK token. Despite this, exchange data shows net outflows, which may ...
ASA Gold & Precious Metals Limited is transitioning from a gold and mining closed-end fund (CEF) to a credit-focused business development company (BDC) managed by Saba, which now owns about 32% of ASA. This shift aims to generate management fees and ...
